Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Sally J Davis; Karen E Sheppard; Michael S Anglesio; Joshy George; Nadia Traficante; Sian Fereday; Maria P Intermaggio; Usha Menon; Aleksandra Gentry-Maharaj; Jan Lubinski; Jacek Gronwald; Celeste Leigh Pearce; Malcolm C Pike; Anna Wu; Stefan Kommoss; Jacobus Pfisterer; Andreas du Bois; Felix Hilpert; Susan J Ramus; David DL Bowtell; David G Huntsman; Richard B Pearson; Kaylene J Simpson; Ian G Campbell; Kylie L Gorringe

Journal article

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Sally J Davis, Karen E Sheppard, Michael S Anglesio, Joshy George, Nadia Traficante, Sian Fereday, Maria P Intermaggio, Usha Menon, Aleksandra Gentry-Maharaj, Jan Lubinski, Jacek Gronwald, Celeste Leigh Pearce, Malcolm C Pike, Anna Wu, Stefan Kommoss, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Susan J Ramus, David DL Bowtell Show all

MOLECULAR CANCER THERAPEUTICS | AMER ASSOC CANCER RESEARCH | Published : 2015

DOI: 10.1158/1535-7163.MCT-15-0039

University of Melbourne Researchers

Kaylene Simpson Author Clinical Pathology

Kylie Gorringe Author The Sir Peter MacCallum Department of Oncology

Richard Pearson Author The Sir Peter MacCallum Department of Oncology

David Bowtell Author The Sir Peter MacCallum Department of Oncology

Ian Campbell Author The Sir Peter MacCallum Department of Oncology

Related Projects (2)

Targetting deregulated signalling pathways in high-grade serous ovarian cancer: Defining therapeutic response and mechanisms of resistance

Ovarian cancer is the major cause of death from gynaecological cancer. Most patients present with advanced disease and die of their cancer. ..

Analysis of ovarian cancer genes

In Australia in 2001 there were ~1300 new cases of ovarian cancer. Survival of ovarian cancer is very poor and current treatments inadequate..

Grants

Awarded by Australian National Health and Medical Research Council

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

K.L. Gorringe was funded by an Australian National Health and Medical Research Council project grant (#566603 and #1043884) and the Emer Casey Foundation (latter also I.G. Campbell). S.J. Davis was supported by a Cancer Council of Victoria Postgraduate Scholarship. The Victorian Centre for Functional Genomics (K.J. Simpson) is funded by the Australian Cancer Research Foundation (ACRF), the Victorian Department of Industry, Innovation and Regional Development (DIIRD), and the Australian Phenomics Network (APN) and supported by funding from the Australian Government's Education Investment Fund through the Super Science Initiative, the Australasian Genomics Technologies Association (AMATA), the Brockhoff Foundation, and the Peter MacCallum Cancer Centre Foundation. D.G. Huntsman and M. Anglesio supported by Canadian Institutes of Health Research Proof of Principle Grant. U. Menon was supported by Cancer Research UK (CRUK). The AGO-OVAR3 study, which contributed to samples in the NanoString assay, was funded by Bristol-Myers-Squibb. UKO was funded by Eve Appeal and supported by researchers at the National Institute for Health Research University College London Hospitals Biomedical Research Centre. A portion of this work was funded by STOP CANCER.